Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) Research & Development (2016 - 2025)

Traws Pharma (TRAW) has disclosed Research & Development for 14 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • For Q4 2025, Research & Development rose 170.99% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $12.1 million, down 5.48%, while the annual FY2025 figure was $12.1 million, 5.48% down from the prior year.
  • Research & Development hit $5.0 million in Q4 2025 for Traws Pharma, up from $2.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $5.1 million in Q3 2024 and bottomed at $1.7 million in Q4 2021.
  • Average Research & Development over 5 years is $2.8 million, with a median of $2.4 million recorded in 2023.
  • Year-over-year, Research & Development tumbled 61.51% in 2021 and then skyrocketed 170.99% in 2025.
  • Traws Pharma's Research & Development stood at $1.7 million in 2021, then soared by 116.22% to $3.8 million in 2022, then crashed by 35.49% to $2.4 million in 2023, then dropped by 23.66% to $1.9 million in 2024, then surged by 170.99% to $5.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $5.0 million, $2.3 million, and $2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.